G. Steven Burrill
Chief Executive Officer

Hal Gerber, MD
Managing Director

Garrett Vygantas, M.D.
Entrepreneur-In-Residence

Stephen M. Sammut, MBA
Venture Partner

Emerging markets (EM) will be the primary driver of pharmaceuticals' forecasted 4.5 percent global annual sales growth to 2020, according to UBS. EM pharma sales will almost equal drug spending in the rest of the world by 2020. Practically everyone in Big Pharma is going after fast-growing drug markets like India, Brazil, China and so on–as blockbuster drugs fall off patent in mature markets, drugmakers try to churn up EM sales to make up the difference. However, the big six emerging markets--Brazil, Russia, India, China, Mexico and Turkey–account for only half of EM sales. Africa, the Middle East and Caspian regions (collectively, AfMET) will experience their share of high growth and exceed USD $35 billion in size within a few years. The challenges of EM are abundant: regulatory, governments, local competition and lower margins – but any biopharmaceutical company without a strategy in place to capture the growth of the EM might face even larger challenges if they chose to ignore.

NewBridge Pharmaceuticals, founded in 2008 by Garrett Vygantas, M.D., Entrepreneur-In-Residence of the Burrill Venture Group, is a first-in-class, venture-backed specialty biopharmaceutical company focused exclusively on licensing and commercializing innovative medical products in the AfMET markets. With headquarters in Dubai, NewBridge is rapidly evolving to become the premier commercialization partner to US, EU and Japanese biopharma companies seeking access to the emerging health care markets of AfMET. Led by Joseph Henein, CEO and a team of highly experienced pharma executives across the region, NewBridge provides unparalleled best practices in regulatory, pharmacovigilance, medical education, finance and supply chain management across this broad and complex geography. In February 2010, NBP had a first close (USD $12MM) of a Series B Preferred Equity round led by Kuwait Life Sciences Company, a subsidiary of NTEC / Kuwait Investment Authority.


DUBAI, UAE:
Phone: +1 610 642 6626
ssammut@b-c.com